FILE 'REGISTRY' ENTERED AT 12:32:15 ON 04 NOV 2002
E FRUCTOYRANOSE SULFAMATE/CN 5
E TOPIRAMATE/CN 5
L1 1 S E3

E EPOETIN ALFA/CN 5
L3 1 S E3

L9 401 S ERYTHROPOIETIN?/CN
L10 402 S L3 OR L9

FILE 'HCAPLUS' ENTERED AT 12:35:51 ON 04 NOV 2002
L1 1 SEA FILE=REGISTRY ABB=ON PLU=ON TOPIRAMATE/CN
L3 1 SEA FILE=REGISTRY ABB=ON PLU=ON "EPOETIN ALFA"/CN
L5 423 SEA FILE=HCAPLUS ABB=ON PLU=ON L1 OR (FRUCTOPYRANOSE OR FRUCTO PYRANOSE)(W)(SULFAMATE OR SULPHAMATE) OR TOPIRAMATE
L9 401 SEA FILE=REGISTRY ABB=ON PLU=ON ERYTHROPOIETIN?/CN
L10 402 SEA FILE=REGISTRY ABB=ON PLU=ON L3 OR L9
L11 5 SEA FILE=HCAPLUS ABB=ON PLU=ON L5 AND (L10 OR ERYTHROPOIETIN OR EPOETIN ALFA)

L11 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2002:637475 HCAPLUS
DOCUMENT NUMBER: 137:163821
TITLE: Treatment of neurological dysfunction comprising **fructopyranose sulfamates** and **erythropoietin**
INVENTOR(S): Plata, Salaman Carlos; Smith-Swintosky, Virginia
PATENT ASSIGNEE(S): Ortho-Mcneil Pharmaceutical, Inc., USA
SOURCE: PCT Int. Appl., 39 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002064085	A2	20020822	WO 2002-US3096	20020124

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-266194P P 20010202
OTHER SOURCE(S): MARPAT 137:163821
AB Co-therapy for the treatment of neurol. dysfunctions comprises administration of one or more **fructopyranose sulfamates** and **erythropoietin**. **Topiramate**

and recombinant human EPO showed synergistic effect on neurite outgrowth of cortical neurons.

IT **11096-26-7, Erythropoietin 97240-79-4, Topiramate 113427-24-0**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(treatment of neurol. dysfunction comprising **fructopyranose sulfamates** and **erythropoietin**)

L11 ANSWER 2 OF 5 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2002:556104 HCAPLUS
DOCUMENT NUMBER: 137:109489
TITLE: Compositions comprising a polypeptide and an active agent
INVENTOR(S): Piccariello, Thomas; Olon, Lawrence P.; Kirk, Randal J.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 34 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002099013	A1	20020725	US 2001-933708	20010822

PRIORITY APPLN. INFO.:

US 2000-247556P	P	20001114
US 2000-247558P	P	20001114
US 2000-247559P	P	20001114
US 2000-247560P	P	20001114
US 2000-247561P	P	20001114
US 2000-247594P	P	20001114
US 2000-247595P	P	20001114
US 2000-247606P	P	20001114
US 2000-247607P	P	20001114
US 2000-247608P	P	20001114
US 2000-247609P	P	20001114
US 2000-247610P	P	20001114
US 2000-247611P	P	20001114
US 2000-247612P	P	20001114
US 2000-247620P	P	20001114
US 2000-247621P	P	20001114
US 2000-247634P	P	20001114
US 2000-247635P	P	20001114
US 2000-247698P	P	20001114
US 2000-247699P	P	20001114
US 2000-247700P	P	20001114
US 2000-247701P	P	20001114
US 2000-247702P	P	20001114
US 2000-247797P	P	20001114
US 2000-247798P	P	20001114
US 2000-247799P	P	20001114
US 2000-247800P	P	20001114
US 2000-247801P	P	20001114
US 2000-247802P	P	20001114
US 2000-247803P	P	20001114

	US 2000-247804P	P	20001114
	US 2000-247805P	P	20001114
	US 2000-247807P	P	20001114
	US 2000-247832P	P	20001114
	US 2000-247833P	P	20001114
	US 2000-247926P	P	20001114
	US 2000-247927P	P	20001114
	US 2000-247928P	P	20001114
	US 2000-247929P	P	20001114
	US 2000-247930P	P	20001114

AB Claimed are compns. comprising a polypeptide and an active agent covalently attached to the polypeptide and a method for delivery of an active agent to a patient by administering the compn. to the patient. The peptide is a homopolymer of a naturally occurring amino acid or a heteropolymer of two or more naturally occurring amino acids. In an example, (Glu)n-cephalexin was prepd. from Glu(OBut)NCA and cephalexin hydrochloride.

IT **97240-79-4, Topiramate 113427-24-0, Epoetin alfa**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. comprising a polypeptide and an active agent)

L11 ANSWER 3 OF 5 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2002:332011 HCAPLUS
DOCUMENT NUMBER: 136:355482
TITLE: Compositions comprising a polypeptide and an active agent
INVENTOR(S): Piccariello, Thomas; Olon, Lawrence P.; Kirk, Randall J.
PATENT ASSIGNEE(S): New River Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 98 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002034237	A1	20020502	WO 2001-US26142	20010822
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2001086599	A5	20020506	AU 2001-86599	20010822

PRIORITY APPLN. INFO.:	US 2000-642820	A	20000822
	WO 2001-US26142	W	20010822

AB Claimed are compns. comprising a polypeptide and an active agent covalently attached to the polypeptide and a method for delivery of an active agent to a patient by administering the compn. to the patient. The peptide is a homopolymer of a naturally occurring

amino acid or a heteropolymer of two or more naturally occurring amino acids. In an example, (Glu)n-cephalexin was prepd. from Glu(OBut)NCA and cephalexin hydrochloride.

IT **97240-79-4, Topiramate 113427-24-0, Epoetin alfa**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. comprising a polypeptide and an active agent)

REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2001:396644 HCAPLUS
DOCUMENT NUMBER: 135:24671
TITLE: Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
INVENTOR(S): Patel, Manesh V.; Chen, Feng-jing
PATENT ASSIGNEE(S): Lipocine, Inc., USA
SOURCE: PCT Int. Appl., 107 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001037808	A1	20010531	WO 2000-US32255	20001122
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6248363	B1	20010619	US 1999-447690	19991123
EP 1233756	A1	20020828	EP 2000-980761	20001122
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				

PRIORITY APPLN. INFO.: US 1999-447690 A 19991123
WO 2000-US32255 W 20001122

AB The present invention provides solid pharmaceutical compns. for improved delivery of a wide variety of pharmaceutical active ingredients contained therein or sep. administered. In one embodiment, the solid pharmaceutical compn. includes a solid carrier, the solid carrier including a substrate and an encapsulation coat on the substrate. The encapsulation coat can include different combinations of pharmaceutical active ingredients, hydrophilic surfactant, lipophilic surfactants and triglycerides. In another embodiment, the solid pharmaceutical compn. includes a solid carrier, the solid carrier being formed of different combinations of pharmaceutical active ingredients, hydrophilic surfactants, lipophilic surfactants and triglycerides. The compns. of the present invention can be used for improved delivery of

hydrophilic or hydrophobic pharmaceutical active ingredients, such as drugs, nutritionals, cosmeceuticals and diagnostic agents. A compn. contained glyburide 1, PEG 40 stearate 33, glycerol monolaurate 17, and nonpareil seed 80 g.

IT **97240-79-4, Topiramate 113427-24-0**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(solid carriers for improved delivery of active ingredients in pharmaceutical compns.)

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 5 OF 5 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2001:300514 HCAPLUS
DOCUMENT NUMBER: 134:331617
TITLE: Oil-in-water emulsion compositions for polyfunctional active ingredients
INVENTOR(S): Chen, Feng-jing; Patel, Mahesh V.
PATENT ASSIGNEE(S): Lipocine, Inc., USA
SOURCE: PCT Int. Appl., 82 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001028555	A1	20010426	WO 2000-US28835	20001018
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2002107265	A1	20020808	US 1999-420159	19991018

PRIORITY APPLN. INFO.: US 1999-420159 A 19991018

AB Pharmaceutical oil-in-water emulsions for delivery of polyfunctional active ingredients with improved loading capacity, enhanced stability, and reduced irritation and local toxicity are described. Emulsions include an aq. phase, an oil phase comprising a structured triglyceride, and an emulsifier. The structured triglyceride of the oil phase is substantially free of triglycerides having three medium chain (C6-C12) fatty acid moieties, or a combination of a long chain triglyceride and a polarity-enhancing polarity modifier. The present invention also provides methods of treating an animal with a polyfunctional active ingredient, using dosage forms of the pharmaceutical emulsions. For example, an emulsion was prepd., with cyclosporin A as the polyfunctional active ingredient dissolved in an oil phase including a structured triglyceride (Captex 810D) and a long chain triglyceride (safflower oil). The compn. contained (by wt.) cyclosporin A 1.0, Captex 810D 5.0, safflower oil 5.0, BHT 0.02, egg phospholipid 2.4, dimyristoylphosphatidyl glycerol 0.2, glycerol 2.25, EDTA 0.01, and water up to 100%, resp.

IT **97240-79-4, Topiramate**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oil-in-water emulsion compns. for polyfunctional active ingredients)
IT **11096-26-7**, Epoetin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(.alpha.; oil-in-water emulsion compns. for polyfunctional active ingredients)
REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 1 SEA FILE=REGISTRY ABB=ON PLU=ON TOPIRAMATE/CN
L3 1 SEA FILE=REGISTRY ABB=ON PLU=ON "EPOETIN ALFA"/CN
L5 423 SEA FILE=HCAPLUS ABB=ON PLU=ON L1 OR (FRUCTOPYRANOSE OR FRUCTO PYRANOSE)(W)(SULFAMATE OR SULPHAMATE) OR TOPIRAMATE
L9 401 SEA FILE=REGISTRY ABB=ON PLU=ON ERYTHROPOIETIN?/CN
L10 402 SEA FILE=REGISTRY ABB=ON PLU=ON L3 OR L9
L12 5 SEA FILE=HCAPLUS ABB=ON PLU=ON L5 AND (L10 OR ERYTHROPOIETIN OR EPOETIN)

=> s l12 not l11
L13 0 L12 NOT L11

(FILE 'MEDLINE, BIOSIS, EMBASE, WPIDS, CONFSCI, SCISEARCH, JICST-EPLUS, JAPIO' ENTERED AT 12:39:32 ON 04 NOV 2002)
L14 8 S L12
L15 5 DUP REM L14 (3 DUPLICATES REMOVED)

L15 ANSWER 1 OF 5 MEDLINE DUPLICATE 1
ACCESSION NUMBER: 2002414413 IN-PROCESS
DOCUMENT NUMBER: 22159038 PubMed ID: 12168506
TITLE: Gateways to Clinical Trials. June 2002.
AUTHOR: Bayes M; Rabasseda X; Prous J Rmbayes@prous.com
SOURCE: METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY, (2002 Jun) 24 (5) 291-327.
Journal code: 7909595. ISSN: 0379-0355.
PUB. COUNTRY: Spain
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: IN-PROCESS; NONINDEXED; Priority Journals
ENTRY DATE: Entered STN: 20020810
Last Updated on STN: 20020810
AB Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the following tables has been retrieved from the Clinical Studies knowledge area of Prous Science Integrity, the drug discovery and development portal, http://integrity.prous.com. This issue focuses on the following selection of drugs: Abacavir sulfate, abarelix, abciximab, alicaforsen sodium, almotriptan, alteplase, amlodipine, amoxicillin trihydrate, amprenavir, argatroban monohydrate, aspirin, atorvastatin calcium, azathioprine; Baclofen, benidipine hydrochloride, benserazide, BMS-214662, bosentan, botulinum toxin type B; Candesartan cilexetil, carbamazepine, carbidopa, carboplatin, ceftriaxone sodium, celecoxib, cetirizine hydrochloride, clarithromycin, clavulanate potassium, clopidogrel

hydrogensulfate, clozapine, CPI-1189, cyclophosphamide, cytarabine; Darbepoetin alfa, denileukin diftitox, dexamethasone, dipyridamole, droperidol, DW-166HC; Ebastine, efalizumab, efavirenz, eletriptan, enalapril maleate, enfuvirtide, enoxaparin sodium, enrasentan, entacapone, **epoetin**, eprosartan mesilate, etanercept, etoricoxib; Fenofibratefexofenadine hydrochloride, filgrastim, fludarabine phosphate, fluoxetine hydrochloride fluvoxamine maleate, frovatriptan, furosemide; Gabapentin, galantamine hydrobromide, gatifloxacin, gefitinib, ghrelin (human), glatiramer acetate; Haloperidol; Ibuprofen, ibuprofen, guaiacol ester, idarubicin hydrochloride, imipramine hydrochloride, imiquimod, interferon beta, interferon beta-1a, interferon beta-1b, interferon omega, irbesartan, itraconazole; Ketorolac, ketorolac tromethamine; Lamifiban, lamotrigine, lanoteplase, lansoprazole, leflunomide, leuprorelin acetate, levetiracetam, levocetirizine, levodopa, lisinopril, loratadine; Manidipine, methylprednisolone, metronidazole, mirtazapine, mizolastine, modafinil, morphine sulfate; Naproxen sodium, naratriptan hydrochloride, nifedipine, NSC-683864; Ofloxacin, olanzapine, omalizumab, omapatrilat, ondansetron hydrochloride, oxcarbazepine; Paclitaxel, parecoxib sodium, paroxetine hydrochloride, phenytoin sodium, pimecrolimus, pramipexole hydrochloride, pravastatin, prednisone, pregabalin; Quetiapine fumarate; Ranitidine hydrochloride, rasburicase, ritonavir, rivastigmine tartrate, rizatriptan benzoate, rofecoxib; Saquinavir mesilate, sertraline, sildenafil citrate, simvastatin, sumatriptan succinate; Tacrolimus, tiagabine hydrochloride, ticlopidine hydrochloride, tirofiban hydrochloride, tolvaptan, **topiramate**, tretinoin; Valproic acid, valsartan, venlafaxine hydrochloride, verapamil; Warfarin sodium; Ximelagatran; Zanamivir, ziconotide, zolmitriptan, zonisamide.

L15 ANSWER 2 OF 5 SCISEARCH COPYRIGHT 2002 ISI (R)
ACCESSION NUMBER: 2002:364309 SCISEARCH
THE GENUINE ARTICLE: 543BL
TITLE: Gateways to clinical trials - March 2002
AUTHOR: Bayes M (Reprint); Rabasseda X; Prous J R
SOURCE: METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY, (MAR 2002) Vol. 24, No. 2, pp. 95-118. Publisher: PROUS SCIENCE, SA, PO BOX 540, PROVENZA 388, 08025 BARCELONA, SPAIN. ISSN: 0379-0355.
DOCUMENT TYPE: General Review; Journal
LANGUAGE: English
REFERENCE COUNT: 134

ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

AB Gateways to Clinical Trials is a guide to the most recent clinical trials ill current literature and congresses. The data in the following tables has been retrieved from the Clinical Studies knowledge area of Prous Science Integrity, the world's first drug discovery and development portal, and provides information on study design, treatments, conclusions and references. This issue focuses oil the following selection of drugs: Alefacept, alendronic acid sodium salt, alteplase, amediplase, aminolevulinic acid hydrochloride, amitriptyline hydrochloride, amlodipine, amoxicillin sodium, amoxicillin trihydrate, amprenavir, amtolmetin guacil, argatroban monohydrate, aspirin, atorvastatin calcium, avasimibe, azelastine hydrochloride; Beclometasone dipropionate, botulinum toxin type A: Calcipotriol, candesartan cilexetil, capecitabine,

cefalexin, celecoxib, cerivastatin sodium, cetirizine hydrochloride, citalopram hydrobromide, clarithromycin, clobetasol propionate, colestyramine, conivaptan hydrochloride; Darbepoetin alfa, desloratadine, dexamethasone, diclofenac sodium, dihydrocodeine bitartrate, DNK-333A; Efalizimab, elinafide mesilate, emtricitabine, enalapril maleate, enoxaparin sodium, eplerenone, **epoetin**, esomeprazole magnesium, etanercept, ezetimibe; Factor VIII gene therapy, fenofibrate, fexofenadine hydrochloride, fondaparinux sodium, furosemide; Gemifloxacin mesilate; Heparin sodium hydrocortisone, hydrochlorothiazide; Ibuprofen, IDEC-131, imatinib mesilate, imiquimod, iodine (1131) tositumomab, irbesartan, iseganan hydrochloride; Lanoteplase, lansoprazole, L-Arginine hydrochloride, loratadine, losartan potassium, lovastatin; Magnesium sulfate, maxacalcitol, metformin hydrochloride, methotrexate, micafungin sodium, mifepristone, morphine sulfate; Naproxen sodium, niacin, nitrendipine, nolomirole hydrochloride, NSC-703940; Olmesartan medoxomil, omalizumab, omapatrilat, omeprazole, omeprazole sodium, oritavancin; Paroxetine, pegvisomant, pethidine hydrochloride, pimecrolimus, piroxicam, pravastatin sodium, prednisone; Quinapril hydrochloride; Ranolazine, rifabutin, rifampicin, rofecoxib, rosiglitazone maleate, rosuvastatin calcium; Sch-48461, Simvastatin; Tacrolimus, telmisartan, tenecteplase, thalidomide, **topiramate**, tramadol hydrochloride, triamcinolone acetonide, troglitazone; Ubidecarenone; Valsartan, vancomycin hydrochloride; Warfarin sodium; Ximelagatran.

L15 ANSWER 3 OF 5 WPIDS (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: 2001-475649 [51] WPIDS
DOC. NO. CPI: C2001-142565
TITLE: Solid composition for delivery of active agents e.g. glyburide comprises carrier optionally containing a substrate having an encapsulation coat containing hydrophilic surfactants e.g. polyoxyethylene alkylethers.
DERWENT CLASS: A96 B05 B07
INVENTOR(S): CHEN, F; PATEL, M V
PATENT ASSIGNEE(S): (LIPO-N) LIPOCINE INC
COUNTRY COUNT: 95
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2001037808	A1	20010531	(200151)*	EN	106
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TR TZ UG ZW					
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW					
US 6248363	B1	20010619	(200151)		
AU 2001017981	A	20010604	(200153)		
EP 1233756	A1	20020828	(200264)	EN	
R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI TR					

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2001037808	A1	WO 2000-US32255	20001122
US 6248363	B1	US 1999-447690	19991123
AU 2001017981	A	AU 2001-17981	20001122
EP 1233756	A1	EP 2000-980761	20001122
		WO 2000-US32255	20001122

FILING DETAILS:

PATENT NO	KIND		PATENT NO
AU 2001017981	A	Based on	WO 200137808
EP 1233756	A1	Based on	WO 200137808

PRIORITY APPLN. INFO: US 1999-447690 19991123
AN 2001-475649 [51] WPIDS
AB WO 200137808 A UPAB: 20021031
NOVELTY - Composition for improved delivery of active agent comprising a solid carrier optionally containing a substrate having an encapsulation coat, where the solid carrier or encapsulation coat contains at least one active agent (I) and one hydrophilic surfactant (II), is new.

ADVANTAGE - The composition is used to deliver a wide variety of active agents having improved absorption and/or biovailability. It provides coated substrate materials without the need for binders. Prior art solid carriers are limited to a few specific drugs due to difficulties in formulating appropriate drug/exicipient compositions to effectively coat the active agent onto a carrier particle. Most of prior art solid dosage forms of hydrophilic active agents exhibit poor or no absorption of the active agent. Non-solid formulations of the same are chemically instable, leak and have capsule shell incompatibility. Conventional solid dosage forms of hydrophobic active agents often exhibit slow and incomplete dissolution and subsequent absorption. They often show a high propensity for biovariability and food interactions of the active agent, resulting in restrictive compliance/labeling requirements. A comparative dissolution study was performed on 3 forms of glyburide (Ia) namely coated beads of (Ia), commercially available (Ia) and pure (Ia) bulk. 5 mg Of each form was usd for triplication dissolution runs in 500 ml of isotonic pH 7.4 phosphate buffer.The dissolutiom medium was sampled at 15, 30, 45, 60, 120 and 180 minutes. The samples were filtered and the filtrates diluted for (Ia)-specific HPLC assay. The (Ia)-coated beads showed a superior dissolution profile in the rate, extent and variability of (Ia) dissolved/released into the medium.
Dwg.0/3

L15 ANSWER 4 OF 5 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
ACCESSION NUMBER: 2002003764 EMBASE
TITLE: Current FDA-related drug information: New drugs approved by the FDA. New dosage forms and indications - Agents pending FDA approval - Labeling changes related to safety.
AUTHOR: Baker D.E.
CORPORATE SOURCE: Dr. D.E. Baker, Drug Information Center, College of Pharmacy, Washington State University, 601 West First

Avenue, Spokane, WA 99201-3899, United States
SOURCE: Hospital Pharmacy, (2001) 36/12 (1278-1289).
ISSN: 0018-5787 CODEN: HOPHAZ
COUNTRY: United States
DOCUMENT TYPE: Journal; General Review
FILE SEGMENT: 037 Drug Literature Index
038 Adverse Reactions Titles
039 Pharmacy
LANGUAGE: English

L15 ANSWER 5 OF 5 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
ACCESSION NUMBER: 2000046771 EMBASE
TITLE: New drugs approved by the FDA: New dosage forms and indications agents pending FDA approval: Major labeling changes.
AUTHOR: Baker D.E.
CORPORATE SOURCE: D.E. Baker, Drug Information Center, College of Pharmacy, Washington State University, 601 West First Avenue, Spokane, WA 99201-3899, United States. Hospitalpharmacy@drugfacts.com
SOURCE: Hospital Pharmacy, (2000) 35/1 (87-98).
ISSN: 0018-5787 CODEN: HOPHAZ
COUNTRY: United States
DOCUMENT TYPE: Journal; General Review
FILE SEGMENT: 037 Drug Literature Index
LANGUAGE: English

=> fil hom
FILE 'HOME' ENTERED AT 12:47:34 ON 04 NOV 2002